umbralisib

chemical compound

Uses your system voice; voice and rate in settings.

Q27088612Snapshot

≈ 1 min read

Names in other languages

  • العربيةأمبراليسيب (دواء)
  • DeutschUmbralisib
  • DeutschUmbralisib
  • DeutschUmbralisib
  • Englishumbralisib
  • EnglishUmbralisib
  • EnglishUmbralisib
  • EspañolUmbralisib

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth. Umbralisib is a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon.

The most common side effects include increased creatinine, diarrhea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash. Umbralisib was granted accelerated approval for medical use in the United States in February 2021.

However, due to concerns for increased long term side effects leading to inferior overall survival which led to increased FDA scrutiny in the form of an ODAC review, it has been withdrawn from the US market.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1331070965 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.